Inflammatory Disease News and Research RSS Feed - Inflammatory Disease News and Research

Fewer patients take effective gout drug after steep price increase

Fewer patients take effective gout drug after steep price increase

Study finds that fewer patients with gout received useful colchicine drug after FDA actions led to 50x increase in price. [More]
Study can aid in developing patient-centered interventions for seniors with asthma

Study can aid in developing patient-centered interventions for seniors with asthma

Although often considered a childhood health problem, asthma - a chronic inflammatory disease that causes recurrent cough, wheezing and chest tightness or shortness of breath - can cause serious illness for people age 60 and older, and little is known about the triggers of asthma specific to seniors. [More]
Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma's CF101Phase II/III psoriasis trial fails to meet primary endpoint

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its Phase II/III psoriasis trial for the Company's drug candidate CF101 did not achieve its primary endpoint. [More]
Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals. [More]
Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Cosentyx (secukinumab) safe, effective for treating psoriasis patients

Novartis today announced new two-year results demonstrating sustained efficacy with Cosentyx (secukinumab) with an acceptable safety profile for the treatment of psoriasis patients. The data comes from the extension study of the pivotal Phase III FIXTURE and ERASURE trials. [More]
New drug-like molecule shows promise in preventing MS progression

New drug-like molecule shows promise in preventing MS progression

Walter and Eliza Hall Institute scientists have developed a new drug-like molecule that can halt inflammation and has shown promise in preventing the progression of multiple sclerosis (MS). [More]
New stem cell treatment reverses disability in certain MS patients

New stem cell treatment reverses disability in certain MS patients

A PIONEERING new stem cell treatment ‘rebooting’ the immune system in some multiple sclerosis sufferers is being hailed as an encouraging step forward in the treatment of the disease in sufferers who fail to respond to standard therapies. [More]
UIC researchers identify genetic variation that increases MS risk in women

UIC researchers identify genetic variation that increases MS risk in women

Researchers at the University of Illinois at Chicago have identified a genetic variation that in women significantly increases their risk of developing multiple sclerosis. [More]
Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics announces positive results from SYM-1219 Phase 1 clinical program

Symbiomix Therapeutics, a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women's health infections, today announced results from its Phase 1 clinical program demonstrating that its lead product candidate, SYM-1219, was safe and well tolerated and had predictable pharmacokinetics (PK), and that contraceptive efficacy for birth control pills would not be altered by SYM-1219 administration. [More]
Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune licenses anti-IL-15 monoclonal antibody from Amgen

Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that it has licensed a Phase 2-stage, anti-IL-15 monoclonal antibody (AMG 714) from Amgen. [More]
FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years. [More]
Scientists discover DNA vaccine that alleviates chronic inflammation in the body

Scientists discover DNA vaccine that alleviates chronic inflammation in the body

An international team of scientists including CureLab Oncology, Inc. (Boston), University of Camerino (Italy), and Boston University have serendipitously discovered a DNA vaccine, which systemically alleviates chronic inflammation in the body. Since osteoporosis is an inflammatory disease, preventive and therapeutic effects of the new vaccine were demonstrated on mouse models with osteoporosis. [More]
Researchers show importance of DNA damage in fine tuning of innate immune system

Researchers show importance of DNA damage in fine tuning of innate immune system

For the first time scientists from Umeå University show the importance of DNA damage in fine tuning of our innate immune system and hence the ability to mount the optimal inflammatory response to infections and other biological dangers. [More]
USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

USPTO issues Notice of Allowance to Can-Fite BioPharma for psoriasis patent

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for CF101 in the treatment of psoriasis. [More]
Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. [More]
Psychedelic drug prevents allergic asthma in mouse model

Psychedelic drug prevents allergic asthma in mouse model

Research led by Charles Nichols, PhD, Associate Professor of Pharmacology and Experimental Therapeutics at the LSU Health New Orleans School of Medicine, has found that a psychedelic drug, (R)-DOI, prevents the development of allergic asthma in a mouse model. [More]
Researchers document pathological progress of multiple sclerosis

Researchers document pathological progress of multiple sclerosis

The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play. [More]
Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma completes patient enrollment in CF101 Phase II/III psoriasis trial

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that all patients enrolled in its Phase II/III psoriasis trial for the Company's drug candidate CF101 have completed the study's 32 week treatment protocol. [More]
Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen's biosimilar Phase 3 rheumatoid arthritis study meets primary and secondary endpoints

Amgen today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira® (adalimumab) in patients with moderate-to-severe rheumatoid arthritis met its primary and key secondary endpoints. [More]
Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

Mobile diagnosis device to help reduce unnecessary antibiotics prescribing

New biosensor-based technology could help to reduce the over-prescribing of antibiotics by giving GPs and other frontline healthcare staff an accurate and fast method of identifying the nature of infectious diseases. [More]
Advertisement
Advertisement